Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial when the cancer returned.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial when the cancer returned.
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
Measuring the level of the tumor marker CA-19-9 is important in determining which treatment to use for pancreatic cancer patients.